Neurocrine Biosciences Unveils New Findings on INGREZZA® vs AUSTEDO XR for Movement Disorders Neurocrine Biosciences has revealed groundbreaking data showcasing how INGREZZA® (valbenazine) exhibits significantly higher VMAT2 target occupancy than AUSTEDO XR. This discovery could enhance treatment options for movement disorders.

Neurocrine Biosciences Unveils New Findings on INGREZZA® vs AUSTEDO XR for Movement Disorders #USA #San_Diego #INGREZZA #Valbenazine #AUSTEDO_XR

Neurocrine Biosciences Announces Disappointing Results of Valbenazine Study for Dyskinetic Cerebral Palsy Neurocrine Biosciences reveals that its Phase 3 study of Valbenazine for treating dyskinetic cerebral palsy did not meet key endpoints. The findings raise concerns for patients.

Neurocrine Biosciences Announces Disappointing Results of Valbenazine Study for Dyskinetic Cerebral Palsy #United_States #San_Diego #Neurocrine_Biosciences #Valbenazine #Dyskinetic_CP